Northbrook, Illinois – September 05, 2026 -- Kalohexis, Inc. has appointed Garry Menzel, Ph.D., to its Board of Directors, adding an executive who raised more than $500 million while leading oncology company TCR2 Therapeutics before its 2023 merger with Adaptimmune.